ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Biomedical Advanced Research and Development Authority (BARDA) is providing $72 million in grants to shore up its flu vaccine supply. The vaccines are aimed at influenza A(H5), which is responsible for the current outbreak of avian flu in dairy cows and a handful of humans. CSL Seqirus, Sanofi, and GSK will use the funds to fill and finish extra doses of their existing H5 vaccines from bulk storage into vials or prefilled syringes. They will also make additional flu antigen so that the shots will be ready to be deployed in an emergency.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X